246 related articles for article (PubMed ID: 28350572)
1. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L
J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil.
Hard ML; Wehr AY; Sadler BM; Mills RJ; von Moltke L
Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):461-469. PubMed ID: 29943125
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L
CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
5. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
Risinger R; Hard M; Weiden PJ
Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
[TBL] [Abstract][Full Text] [Related]
6. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.
Hard ML; Wehr AY; Du Y; Weiden PJ; Walling D; von Moltke L
J Clin Psychopharmacol; 2018 Oct; 38(5):435-441. PubMed ID: 30015676
[TBL] [Abstract][Full Text] [Related]
8. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
Citrome L
Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole Lauroxil: A Review in Schizophrenia.
Frampton JE
Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
Aggarwal A; Gopalakrishna G; Lauriello J
Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
Wang Y; Harlin M; Larsen F; Wang X; Park W; Rich B; Gobburu JV; Raoufinia A
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):631-643. PubMed ID: 38602057
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole Lauroxil NanoCrystal
Ehret MJ; Davis E; Luttrell SE; Clark C
Clin Schizophr Relat Psychoses; 2018; 12(2):92-96. PubMed ID: 30040476
[TBL] [Abstract][Full Text] [Related]
14. Initiation of aripiprazole once-monthly in patients with schizophrenia.
Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
16. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
[TBL] [Abstract][Full Text] [Related]
17. Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique.
Farwick S; Hickey MB; Jacobs G; Faldu SP; Vandiver J; Weiden PJ
J Psychiatr Pract; 2019 Mar; 25(2):82-90. PubMed ID: 30849056
[TBL] [Abstract][Full Text] [Related]
18. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals.
Sommi RW; Rege B; Wehr A; Faldu S; Du Y; Weiden PJ
CNS Spectr; 2022 Jun; 27(3):262-267. PubMed ID: 33267924
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
Eum S; Schneiderhan ME; Brown JT; Lee AM; Bishop JR
BMC Psychiatry; 2017 Jul; 17(1):238. PubMed ID: 28673279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
